Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fenaux

Showing results (181-190 of 432) with videos related to

Pageof 44
Sort By:
British Journal of Clinical Pharmacology|January 9, 2020
Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in VigibaseJustine Perino, Nathan Mottal, Yohann Bohbot, et al.
Blood|March 25, 2015
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cellsHiba El Hajj, Zeina Dassouki, Caroline Berthier, et al.
Cell Cycle (Georgetown, Tex.)|June 10, 2011
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemiaSylvain Thépot, Elodie Lainey, Thomas Cluzeau, et al.
Haematologica|December 31, 2016
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, et al.
Blood|May 3, 2002
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML IntergroupStéphanie Nguyen, Thierry Leblanc, Pierre Fenaux, et al.
Blood Advances|April 18, 2025
Prognostic Significance of Monocytic-like Phenotype in AML patients treated with Venetoclax and AzacytidineLin-Pierre Zhao, Typhaine Dumas-Rivero, Lauren Barette, et al.
Blood|November 7, 2008
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 studyLionel Adès, Simone Boehrer, Thomas Prebet, et al.
Leukemia Research|June 29, 2010
Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patientsSophie Park, Charikleia Kelaidi, Rosa Sapena, et al.
Annals of Hematology|May 10, 2011
Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma levelLaurence Legros, Bohrane Slama, Jean-Michel Karsenti, et al.
Advances in Therapy|May 16, 2025
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS TrialGuillermo Garcia-Manero, Valeria Santini, Amer M Zeidan, et al.
Pageof 44

Showing results (181-190 of 432) with videos related to

Sort By:
Pageof 44
British Journal of Clinical Pharmacology|January 9, 2020
Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in VigibaseJustine Perino, Nathan Mottal, Yohann Bohbot, et al.
Blood|March 25, 2015
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cellsHiba El Hajj, Zeina Dassouki, Caroline Berthier, et al.
Cell Cycle (Georgetown, Tex.)|June 10, 2011
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemiaSylvain Thépot, Elodie Lainey, Thomas Cluzeau, et al.
Haematologica|December 31, 2016
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, et al.
Blood|May 3, 2002
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML IntergroupStéphanie Nguyen, Thierry Leblanc, Pierre Fenaux, et al.
Blood Advances|April 18, 2025
Prognostic Significance of Monocytic-like Phenotype in AML patients treated with Venetoclax and AzacytidineLin-Pierre Zhao, Typhaine Dumas-Rivero, Lauren Barette, et al.
Blood|November 7, 2008
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 studyLionel Adès, Simone Boehrer, Thomas Prebet, et al.
Leukemia Research|June 29, 2010
Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patientsSophie Park, Charikleia Kelaidi, Rosa Sapena, et al.
Annals of Hematology|May 10, 2011
Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma levelLaurence Legros, Bohrane Slama, Jean-Michel Karsenti, et al.
Advances in Therapy|May 16, 2025
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS TrialGuillermo Garcia-Manero, Valeria Santini, Amer M Zeidan, et al.
Pageof 44